Compare GSK plc (GSK) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B). The key difference: GSK plc is far larger — about 3.4× iShares 1 3 Year Treasury Bond ETF's market cap, and GSK plc pays a 3.9% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| GSK | SHY | |
|---|---|---|
Market Cap | $91.88B | $26.68B |
Volume | 7,730,529 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $83.18 |
52-Week Low | $43.24 | $81.05 |
Typical Hold Time | 93 Days | 63 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SHY trades at $81.185 with minimal daily movement (+0.03%), reflecting stability amid broader bond market volatility. The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend payments of $0.24-$0.25 demonstrate consistent income distribution. The fund operates in a challenging environment with rising Treasury yields impacting bond valuations.
SHY faces headwinds from the ongoing bond market selloff and rising interest rates, which pressure short-term bond ETFs. However, the fund's structure provides relative stability compared to longer-duration instruments. The primary risk remains further Fed tightening, while the opportunity lies in capital preservation during market turbulence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
